| Authors: |
Dagnew AF; Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA. Electronic address: alemnew.dagnew@gatesmri.org., Han LL; Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA., Naidoo K; CAPRISA-South African Medical Research Council (SAMRC) TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine, Durban, South Africa., Fairlie L; Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Innes JC; The Aurum Institute, Clinical Research Division, Aurum Klerksdorp Clinical Research, Klerksdorp, South Africa., Middelkoop K; Desmond Tutu HIV Center, Institute of Infectious Disease and Molecular Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa., Tameris M; South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Wilkinson RJ; Wellcome Discovery Research Platforms in Infection, Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa; Francis Crick Institute, London, UK; Department of Infectious Diseases, Imperial College London, London, UK., Ananworanich J; Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA., Bower D; Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA., Schlehuber L; Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA., Frahm N; Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA., Cinar A; Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA., Dunne M; Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA., Schmidt AC; Gates Medical Research Institute, Clinical Development, Cambridge, MA, USA. |
